Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

October 19, 2022

BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in three presentations at the upcoming International Congress for Ataxia Research. The conference will take place November 1 – 4, 2022, in Dallas, Texas.

Details on the presentations are shown below.

Title:	Safety and Pharmacokinetics of Single and 13 Day Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy for Friedreich’s Ataxia
Presentation Format:	Oral
Presenting Author:	Nancy M. Ruiz, MD, Chief Medical Officer, Larimar Therapeutics
Presentation Date and Time:	November 3, 2022, at 4:00 PM CT

Title:	Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Presentation Format:	Poster
Presenting Author:	David Bettoun, PhD, Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics
Poster Session Date and Time:	12:00 -1:00 PM CT on November 2 and 3, 2022

Title:	Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients
Presentation Format:	Poster
Presenting Author:	Matthew Baile, PhD, Senior Research Investigator, Larimar Therapeutics
Poster Session Date and Time:	12:00 -1:00 PM CT on November 2 and 3, 2022

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

Source: Larimar Therapeutics